Strathcona County

Patients and Doctors Agree on Treatment Goals Only Half the Time, According to JNCCN Study on People with Neuroendocrine Tumors

Retrieved on: 
Monday, December 12, 2022
Oncology, Associate professor, Fox Chase Cancer Center, Prostate, Health, Cancer, Professor, Neoplasm, NCCN, Policy, Patient, Associate, SCM, City, Pharmacist, Wilms' tumor, Pharmacology, Fatigue, Duke Cancer Institute, University of Michigan Rogel Cancer Center, Bioethics, MPH, University, National Comprehensive Cancer Network, Dizziness, MD Anderson Cancer Center, Overalls, NETS, Education, MBA, Harborside, Report, Hematology, JD, Chair, Internal medicine, Haematopoietic system, City of Hope, Communication, Duke University Hospital, Mayo Clinic Cancer Center, UCSF, Strathcona County, Survival, Caregiver, UCSF Helen Diller Family Comprehensive Cancer Center, Life expectancy, Public policy, Medical imaging, Pharmaceutical industry, Research, Epidemiology, MD, Medicine, Hope, UAB, Doctor of Philosophy

PLYMOUTH MEETING, Pa., Dec. 12, 2022 /PRNewswire/ -- New research from cancer research and treatment organization City of Hope in the December 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. The remaining patients selected other single specific treatment goals as most important, such as maintaining the ability to do daily activities, reducing or eliminating pain, or reducing or eliminating symptoms like fatigue. 66.7% of those surveyed agreed with the statement: "I would rather live a shorter life than lose my ability to take care of myself."

Key Points: 
  • However, respondents felt their doctors were more singularly focused on extending overall survival, even if it impacted other outcomes.
  • Only 51.7% of patients perceived that they had the same treatment goals as their physician.
  • Complimentary access to " Patient-Defined Goals and Preferences Among Adults With Advanced Neuroendocrine Tumors " is available until March 10, 2023.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Susan G. Komen® Names Dr. Ann H. Partridge as New Chief Scientific Advisor

Retrieved on: 
Wednesday, December 7, 2022
Vanderbilt University Medical Center, Dana–Farber Cancer Institute, Oncology, Breast cancer, Harvard University, Research, Health, Patient, Bernard Pietenpol, Cancer, Eric, Disease, Susan G. Komen for the Cure, Medicine, MPH, Woman, Strathcona County, Quality of life, United States Air Force Scientific Advisory Board, Dietary supplement, Management, MD

DALLAS, Dec. 7, 2022 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced Ann H. Partridge, MD, MPH, as Chief Scientific Advisor, where she will help identify the greatest needs and opportunities to invest in breast cancer research and guide Komen's research strategy, investment, and programs. In her role, she will co-lead an executive committee of eight distinguished breast cancer researchers, clinicians and patient advocates who make up Komen's Scientific Advisory Board.

Key Points: 
  • Ann H. Partridge, MD, MPH, has been named Chief Scientific Advisor for Susan G. Komen.
  • "Susan G. Komen is honored to have Dr. Partridge serve as Komen's new Chief Scientific Advisor.
  • Partridge replaces George Sledge, Jr., MD, who served as Chief Scientific Advisor for 10 years, and will serve alongsideJennifer Pietenpol, Ph.D. Pietenpol is the Chief Scientific and Strategy Officer at Vanderbilt University Medical Center.
  • This is the first time Komen has had two women serving simultaneously in the Chief Scientific Advisor roles.

Karmanos Cancer Institute Receives the Women's Choice Award® as one of America's Best Hospitals for Cancer Care for 10th consecutive year

Retrieved on: 
Tuesday, December 6, 2022
Courage, Women's Choice Awards, Karmanos, Patient satisfaction, MSA, Hospital, Accreditation, Wayne State University School of Medicine, Karmanos Cancer Institute, McLaren Health Care Corporation, National Cancer Institute, Partnership, Patient, RN, Cancer, Karger Publishers, Research, Huntsman Cancer Institute, Breast cancer, Woman, Strathcona County, Health care, ACS, Wayne, Subclinical infection, Multimedia, Education, University School, Health, NCI, Medicine, Pharmaceutical industry

DETROIT, Dec. 6, 2022 /PRNewswire/ -- For the 10th consecutive year, the Barbara Ann Karmanos Cancer Institute has been named one of America's Best Hospitals for Cancer Care by the Women's Choice Award®, America's trusted referral source for the best in health care. The award signifies that Karmanos is in the top 10 percent of 4,729 U.S. hospitals offering cancer care services. Karmanos has received this honor since the inception of the award in 2014.

Key Points: 
  • DETROIT, Dec. 6, 2022 /PRNewswire/ -- For the 10th consecutive year,the Barbara Ann Karmanos Cancer Institute has been named one of America's Best Hospitals for Cancer Care by the Women's Choice Award , America's trusted referral source for the best in health care.
  • America's Best Hospitals for Cancer Care by the Women's Choice Award also ranked the NCI-designated comprehensive cancer center inthe topeight percentfor Breast Care and the topfive percentfor Mammogram Imaging.
  • Passi emphasized that Karmanos Cancer Institute and all the 2023 America's Best Hospitals for Cancer Care deliver the care that matters most to women.
  • The Barbara Ann Karmanos Cancer Institute is one of 459 award recipients representing the hospitals that have met the highest standards for cancer care inthe U.S.by the Women's Choice Award.

Leading National Prostate Cancer Nonprofit Spearheads Influential HHS Moonshot Meeting

Retrieved on: 
Friday, December 2, 2022
Policy, Prostate cancer, Health equity, White, Lobbying, HHS, White House, Research, Cancer, NIH, DOD, Investment, Patient, Strathcona County, CDC, Education, Government, ZERO, Birth control, Medical imaging

WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- OCCASION: ZERO - The End of Prostate Cancer was invited to convene a White House discussion on prostate cancer as a part of the Biden administration's Cancer Moonshot Initiative. Launched in 2016, the Biden administration intends to reduce the national death rate from cancer by at least 50% over the next 25 years and improve the experience of people and their families living with and surviving cancer.

Key Points: 
  • WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- OCCASION: ZERO - The End of Prostate Cancer was invited to convene a White House discussion on prostate cancer as a part of the Biden administration's Cancer Moonshot Initiative .
  • WHY: Over 3 million men are living with prostate cancer, making it the most commonly diagnosed cancer among American men.
  • Black men are almost twice as likely to be diagnosed with prostate cancer and over twice as likely to die from prostate cancer as White men.
  • ZERO The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted.

ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards

Retrieved on: 
Thursday, December 1, 2022
ALK, Life expectancy, Human, Doctor of Philosophy, Helpline, EML4-ALK positive lung cancer, Clinical trial, Conference, Smoker, Cancer, Multimedia, Large-cell lung carcinoma, Partnership, Caregiver, Patient, Anaplastic lymphoma kinase, Charity Navigator, Health equity, Disease, MD, Lung cancer, Public policy, Research, BUT, Quality of life, MPH, Survival, Strathcona County, FDA, Pharmaceutical industry, Medical imaging

WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. The grant monies, totaling $1.75 million, were raised by ALK Positive and represent patients with ALK-positive non-small cell lung cancer themselves directly influencing the direction and focus of the research that affects their lives. This year's awardees are the third cohort to receive these awards.

Key Points: 
  • To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program
    WASHINGTON, Dec. 1, 2022 /PRNewswire/ -- Patient organization ALK Positive, in partnership with LUNGevity Foundation, announced the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards.
  • The recipients of the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are:
    "We are thrilled to continue our partnership with ALK Positive through these impactful research awards," said Upal Basu-Roy, PhD, MPH, executive director of research at LUNGevity Foundation.
  • The three scientists selected for the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are international experts in the field.
  • ALK Positive has implemented multiple programs to improve care for ALK- positive cancer patients, and accelerate the development and availability of improved treatments.

FlowPlay Surpasses $550,000 Milestone in Funds Raised for American Cancer Society

Retrieved on: 
Tuesday, November 29, 2022
Partner, ACS, Diagnosis, Navigation, Caregiver, Patient, Transport, Patient navigators, Vegas World, American Cancer Society, Grandiosity, News, Intel Capital, Cancer, Pacific Northwest, Sport, Entrepreneurship, Community Impact Newspaper, OurWorld, Strathcona County, Pharmaceutical industry, Casino, Skype

SEATTLE, Nov. 29, 2022 /PRNewswire/ -- FlowPlay, creator of one of the most powerful connected gaming platforms, today announced its Vegas World in-game fundraisers have surpassed $550,000 raised for the American Cancer Society (ACS). This news comes on the heels of FlowPlay's most recent campaign, which raised $60,000 for ACS's Patient Navigation Program. FlowPlay also celebrates over one million charms sold for ACS, a major driver of overall fundraising.

Key Points: 
  • SEATTLE, Nov. 29, 2022 /PRNewswire/ -- FlowPlay , creator of one of the most powerful connected gaming platforms, today announced its Vegas World in-game fundraisers have surpassed $550,000 raised for the American Cancer Society (ACS).
  • In October, FlowPlay offered a virtual branded charm in the company's flagship connected game, Vegas World , which was available for players to purchase.
  • "The American Cancer Society is so grateful to FlowPlay, and specifically to Vegas World players, for their generous support of patient navigation, transportation, and other lifesaving programs for cancer patients," said Paula Aspiazu, Vice President, Community Impact, American Cancer Society.
  • To learn more about the American Cancer Society and how to donate, please visit: http://www.cancer.org .

American Oncology Network Celebrates Physician Ambassadors of the Real Men Wear Pink Campaign

Retrieved on: 
Monday, November 21, 2022
Pathology, Diagnosis, Ambassador, Cancer, Breast Cancer Awareness Month, Physician, Patient, Practitioner, Friends, Oncology, American Cancer Society, AON, Disease, Breast cancer, DRS, Research, Family, Strathcona County, Woman, Degenerative disease, Birth control, Medical imaging, Medicine

FORT MYERS, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) wrapped up Breast Cancer Awareness month recognizingits physicians who participated in the nationwide Real Men Wear Pink campaign: Dr. Christopher McCanless from Hematology Oncology Clinic in Baton Rouge, Louisiana, and Drs.

Key Points: 
  • FORT MYERS, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) wrapped up Breast Cancer Awareness month recognizingits physicians who participated in the nationwide Real Men Wear Pink campaign: Dr. Christopher McCanless from Hematology Oncology Clinic in Baton Rouge, Louisiana, and Drs.
  • The Real Men Wear Pink campaign , an initiative of the American Cancer Society, is a nationwide movement to raise money and increase awareness of breast cancer.
  • The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology.
  • Launched in 2018, the rapidly expanding AON network represents 108 physicians and 86 nurse practitioners and physician assistants practicing across 16 states.

Thankfulness: A Caregiver's Story

Retrieved on: 
Friday, November 18, 2022
COVID-19, Gordon Gano, Human, Emotion, Diagnosis, Patient, Strathcona County, Lung cancer, Reed, Tears, Meritus University, Medicine, Medical imaging

In 2020, as the COVID-19 pandemic was in full swing, Fares was diagnosed with lung cancer.

Key Points: 
  • In 2020, as the COVID-19 pandemic was in full swing, Fares was diagnosed with lung cancer.
  • It was shortly after the diagnosis, that Reed was introduced to Mary Ann Ganoe, a clinical navigator at Meritus Medical Centers John R. Marsh Cancer Center.
  • Anytime I needed to know something or needed anything at all, Mary Ann would break down the information for me.
  • Clinical navigators, sometimes called patient navigators, make sure that no one walks the journey of a cancer diagnosis alone.

Healthcare Technology Leader Laure Tessier-Delivuk Joins Inspirata as Vice President of Operations for Oncology Informatics

Retrieved on: 
Thursday, November 17, 2022
Pathology, Institut National d'Optique, Operational definition, Artificial intelligence, Design, Creativity, Patient, PMP, GE Healthcare, Operation, Informatics, Computer Sciences, Marketing, INSEAD, Integrating the Healthcare Enterprise, Business operations, Training, Medical imaging, Development, IEEE Medal for Innovations in Healthcare Technology, Medicine, Human resources, Strathcona County, Training and development, Business, Management, Tebenna inspirata, Finance, Engineering

Effective November 17, 2022, Laure Tessier-Delivuk, PMP, has joined as Vice President of Operations Oncology Informatics.

Key Points: 
  • Effective November 17, 2022, Laure Tessier-Delivuk, PMP, has joined as Vice President of Operations Oncology Informatics.
  • Laure brings 25+ years of experience as a Healthcare Technology executive leader and a proven track record in managing multimillion-dollar business units to achieve revenue, profit, and growth objectives.
  • Laure will tap into more than two decades of progressive achievement with GE Healthcare (GEHC), a leading global medical technology and digital solutions innovator.
  • Most recently, Laure worked on accelerating healthcare innovation with artificial intelligence and previously served as Senior Director of Business Operations for GE Healthcare Digital.

Katherine Rundell's Super-Infinite: The Transformations of John Donne Wins the Baillie Gifford Prize for Non-Fiction 2022

Retrieved on: 
Thursday, November 17, 2022
Penguin Random House, Rundell, Science, Baillie Gifford Prize, The Times Literary Supplement, MP, The New York Times, History, Editing, Bookselling, Picador, The Escape Artist, Dean of St Paul's, Life, The Sunday Times, Pan Books, Escape, Empire of Pain, Travel, Dean, Autobiography, Empire, Science Museum, BBC, London, Biography, All Souls College, Oxford, The London Review, Restless, Politics, Love, The Bodley Head, Transformation, Country Doctor, The Bookseller, Obsessions, Old, Baillie Gifford, The New York Review of Books, Animal, Strathcona County, HarperCollins, Cathedral, READ, Television, Book, Hachette, Pain, Violence, Renaissance, New Yorker

LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Super-Infinite: The Transformations of John Donne by Katherine Rundell has been named winner ofthe Baillie Gifford Prize for Non-Fiction 2022.

Key Points: 
  • LONDON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Super-Infinite: The Transformations of John Donne by Katherine Rundell has been named winner ofthe Baillie Gifford Prize for Non-Fiction 2022.
  • The announcement was streamed to readers around the world via the Baillie Gifford Prize social media channels.
  • Super-Infinite: The Transformations of John Donne gives readers a window into the little-known myriad lives the poet John Donne lived.
  • The Baillie Gifford Prize aims to recognise and reward the best of non-fiction and is open to authors of any nationality.